To include your compound in the COVID-19 Resource Center, submit it here.

Biogen gains MS candidate from Alkermes

On Nov. 27, Biogen Inc. (NASDAQ:BIIB) obtained an exclusive, worldwide license to commercialize multiple sclerosis candidate ALKS 8700 from Alkermes plc (NASDAQ:ALKS), removing a potential competitor to Biogen’s blockbuster MS drug Tecfidera dimethyl fumarate

Read the full 342 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE